LAG3 and hematologic disorder: Furthermore, Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that inhibits both PD-1 and LAG-3, was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort-expansion clinical trial in adult patients with solid tumors or hematologic malignancies with disease progression on previous treatment (ClinicalTrials.gov identifier: NCT03219268) [36].